home All News open_in_new Full Article

Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect

Biotech firm Ascletis Pharma said ASC47, its muscle-preserving weight loss drug candidate, could boost the efficacy of the popular anti-obesity medication semaglutide by 56.2 per cent, as Chinese drug makers eye a growing share of this lucrative market. That finding came from a trial that Ascletis conducted in the US for 28 participants with obesity, which aimed to assess the drug candidate’s safety and ideal dose, according to the company’s statement on Monday. The treatment duration was four...


today last month attach_file Events

attach_file Politics
attach_file Economics
attach_file Politics
attach_file Economics
attach_file Events
attach_file Politics
attach_file Events
attach_file Events
attach_file Politics
attach_file Events
attach_file Events
attach_file Economics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events


ID: 1257343914
Add Watch Country

arrow_drop_down